Inefficacy of Immunosuppressive Therapy for Severe Aplastic Anemia Progressing From Non-SAA: Improved Outcome After Allogeneic Hematopoietic Stem Cell Transplantation

被引:3
|
作者
Liu, Limin [1 ]
Zhao, Xin [2 ]
Miao, Miao [1 ]
Zhang, Yanming [3 ,4 ]
Jiao, Wenjing [5 ]
Lei, Meiqing [6 ]
Zhou, Huifen [1 ]
Wang, Qingyuan [1 ]
Cai, Yifeng [7 ]
Zhao, Liyun [8 ]
Shangguan, Xiaohui [9 ]
Liu, Zefa [10 ]
Xu, Jinge [11 ]
Zhang, Fengkui [2 ]
Wu, Depei [1 ]
机构
[1] Soochow Univ, Natl Clin Res Ctr Hematol Dis, Jiangsu Inst Hematol, Affiliated Hosp 1, Suzhou, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Coll, State Key Lab Expt Hematol, Natl Clin Res Ctr Blood Dis, Anemia Therapeut Ctr,Inst Hematol & Blood Dis Hos, Tianjin, Peoples R China
[3] Xuzhou Med Univ, Dept Hematol, Affiliated Huaian Hosp, Huaian, Peoples R China
[4] Second Peoples Hosp Huaian, Huaian, Peoples R China
[5] Xian Yang Cent Hosp, Dept Hematol, Xianyang, Peoples R China
[6] Cent South Univ, Dept Hematol, Haikou Municipal Peoples Hosp, Affiliated Haikou Hosp,Xiangya Sch Med, Haikou, Hainan, Peoples R China
[7] Nantong Univ, Dept Hematol, Affiliated Hosp, Nantong, Peoples R China
[8] People Hosp Xingtai, Dept Hematol, Xingtai, Peoples R China
[9] Fujian Med Univ, Dept Hematol, Longyan Hosp 1, Longyan, Peoples R China
[10] People Hosp Xinghua, Dept Hematol, Xinghua, Peoples R China
[11] Xuzhou Med Univ, Dept Hematol, Affiliated Hosp 2, Xuzhou, Jiangsu, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2021年 / 11卷
基金
国家重点研发计划;
关键词
severe aplastic anemia; immunosuppressive therapy; hematopoietic stem cell transplantation; first-line therapy; outcome; BONE-MARROW-TRANSPLANTATION; HIGH-DOSE CYCLOPHOSPHAMIDE; ANTI-THYMOCYTE GLOBULIN; ANTITHYMOCYTE GLOBULIN; POSTTRANSPLANTATION CYCLOPHOSPHAMIDE; CYCLOSPORINE; GUIDELINES; MANAGEMENT; DIAGNOSIS; CHILDREN;
D O I
10.3389/fonc.2021.739561
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background and Aims This study aimed at comparing the efficacy and safety of severe aplastic anemia (SAA) cases that had met the criteria for SAA at the time of diagnosis (group A) with SAA that had progressed from non-SAA (NSAA) (group B), both undergoing first-line immunosuppressive therapy (IST). Additionally, group B was compared with SAA that had progressed from NSAA and who had been treated by allogeneic hematopoietic stem cell transplantation (allo-HSCT) (group C).</p> Methods We retrospectively compared 608 consecutive patients in group A (n = 232), group B (n = 229) and group C (n = 147) between June 2002 and December 2019. Six months after treatment, the rate of overall response and the fraction of patients who had achieved normal blood values, treatment-related mortality (TRM), secondary clonal disease, 5-year overall survival (OS) and failure-free survival (FFS) were indirectly compared between group A and group B, group B and group C.</p> Results Six months after treatment, the rate of overall response and the fraction of patients who had achieved normal blood values in group A was higher than in group B (65.24% vs. 40.54%, P < 0.0001; 23.33% vs. 2.25%, P < 0.0001); the same was true for group C (92.50% vs. 2.25%, P < 0.0001). The rate of relapse in group B was higher than in group C (P < 0.0001), but there were no differences in TRM and secondary clonal disease (P > 0.05). There were no differences in estimated 5-year OS between groups A and B (83.8% +/- 2.6% vs. 85.8% +/- 2.6%, P = 0.837), or between B and C (85.8% +/- 2.6% vs. 77.9% +/- 3.4%, P = 0.051). The estimated 5-year FFS in groups A and C was higher than for group B (57.1% +/- 3.3% vs. 39.7% +/- 3.4%, P < 0.001; 76.7% +/- 3.5% vs. 39.7% +/- 3.4%, P < 0.0001).</p> Conclusion These results indicate that IST is less effective in SAA progressing from non-SAA but allo-HSCT can improve outcomes.</p>
引用
收藏
页数:10
相关论文
共 50 条
  • [21] Allogeneic Hematopoietic Stem Cell Transplant for Severe Aplastic Anemia: Current State and Future Directions
    Sun, Qixin
    Wu, Bingyi
    Zhu, Zhigang
    Sun, Can
    Xu, Jingxia
    Long, Hui
    Huang, Yuxian
    Xu, Jianhui
    Song, Chaoyang
    CURRENT STEM CELL RESEARCH & THERAPY, 2018, 13 (05) : 350 - 355
  • [22] First-Line Matched Related Donor Hematopoietic Stem Cell Transplantation Compared to Immunosuppressive Therapy in Acquired Severe Aplastic Anemia
    Peinemann, Frank
    Grouven, Ulrich
    Kroeger, Nicolaus
    Bartel, Carmen
    Pittler, Max H.
    Lange, Stefan
    PLOS ONE, 2011, 6 (04):
  • [23] Excellent Outcome of Haploidentical Hematopoietic Stem Cell Transplantation in Children and Adolescents with Acquired Severe Aplastic Anemia
    Im, Ho Joon
    Koh, Kyung Nam
    Choi, Eun Seok
    Jang, Seongsoo
    Kwon, Seog Woon
    Park, Chan-Jeoung
    Chi, Hyun-Sook
    Seo, Jong Jin
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2013, 19 (05) : 754 - 759
  • [24] Matched Sibling Versus Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation in Children with Severe Acquired Aplastic Anemia: Experience of the Polish Pediatric Group for Hematopoietic Stem Cell Transplantation
    Szpecht, Dawid
    Gorczynska, Ewa
    Kalwak, Krzysztof
    Owoc-Lempach, Joanna
    Choma, Marta
    Styczynski, Jan
    Gozdzik, Jolanta
    Dluzniewska, Agnieszka
    Wysocki, Mariusz
    Kowalczyk, Jerzy R.
    Chybicka, Alicja
    Pieczonka, Anna
    Wachowiak, Jacek
    ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS, 2012, 60 (03) : 225 - 233
  • [25] Outcome of Allogeneic Hematopoietic Cell Transplantation from HLA-Identical Siblings for Severe Aplastic Anemia in Patients Over 40 Years of Age
    Sangiolo, Dario
    Storb, Rainer
    Deeg, H. Joachim
    Flowers, Mary E. D.
    Martin, Paul J.
    Sandmaier, Brenda M.
    Kiem, Hans-Peter
    Nash, Richard A.
    Doney, Kris
    Leisenring, Wendy M.
    Georges, George Earl
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2010, 16 (10) : 1411 - 1418
  • [26] Second allogeneic hematopoietic stem cell transplantation in children with severe aplastic anemia
    Kudo, K.
    Muramatsu, H.
    Yoshida, N.
    Kobayashi, R.
    Yabe, H.
    Tabuchi, K.
    Kato, K.
    Koh, K.
    Takahashi, Y.
    Hashii, Y.
    Kawano, Y.
    Inoue, M.
    Cho, Y.
    Sakamaki, H.
    Kawa, K.
    Kato, K.
    Suzuki, R.
    Kojima, S.
    BONE MARROW TRANSPLANTATION, 2015, 50 (10) : 1312 - 1315
  • [27] Outcome of allogeneic hematopoietic stem cell transplantation in adult patients with hepatitis-associated aplastic anemia
    Mori, Takehiko
    Onishi, Yasushi
    Ozawa, Yukiyasu
    Kato, Chiaki
    Kai, Tatsuyuki
    Kanda, Yoshinobu
    Kurokawa, Mineo
    Tanaka, Masatsugu
    Ashida, Takashi
    Sawayama, Yasushi
    Fukudan, Takahiro
    Ichinohe, Tatsuo
    Atsuta, Yoshiko
    Yamazaki, Hirohito
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2019, 109 (06) : 711 - 717
  • [28] Haploidentical hematopoietic stem cell transplantation for nonresponders to immunosuppressive therapy against acquired severe aplastic anemia
    Liu, L.
    Wang, X.
    Jin, S.
    Hao, L.
    Zhang, Y.
    Zhang, X.
    Wu, D.
    BONE MARROW TRANSPLANTATION, 2016, 51 (03) : 424 - 427
  • [29] ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IS SUPERIOR TO IMMUNOSUPPRESSIVE THERAPY IN INDIAN CHILDREN WITH APLASTIC ANEMIA-A SINGLE-CENTER ANALYSIS OF 100 PATIENTS
    George, Biju
    Mathews, Vikram
    Viswabandya, Auro
    Lakshmi, Kavitha M.
    Srivastava, Alok
    Chandy, Mammen
    PEDIATRIC HEMATOLOGY AND ONCOLOGY, 2010, 27 (02) : 122 - 131
  • [30] Allogeneic stem cell transplantation for severe aplastic anemia: Graft rejection remains a problem
    Aki, Sahika Zeynep
    Sucak, Gulsan Turkoz
    Oezkurt, Zubeyde Nur
    Yegin, Zeynep Arzu
    Yagci, Munci
    Haznedar, Rauf
    TRANSFUSION AND APHERESIS SCIENCE, 2009, 40 (01) : 5 - 11